IDEAS home Printed from https://ideas.repec.org/a/eee/socmed/v37y1993i4p541-547.html
   My bibliography  Save this article

Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy--How does this compare to existing neonatal screening for metabolic disorders?

Author

Listed:
  • Rosenberg, T.
  • Jacobs, H.K.
  • Thompson, R.
  • Horne, J.M.

Abstract

Costs of screening a series of 18, 152 newborn males for Duchenne muscular dystrophy (DMD) in Canada were evaluated. The final aim of neonatal screening for DMD is the avoidance of additional cases in the families identified. Total costs to avoid one case of DMD were estimated at Cdn. $172,000, while the incremental costs were found to be $83,000. Reagent costs, test sensitivity, efficacy of screening and compliance with genetic advice were identified as factors crucial for cost-effectiveness. Costs of neonatal screening for DMD are compared with costs of neonatal screening for inborn metabolic disorders. It is found that the two programmes are similar in costs. Earlier predictions of inordinate costs of screening for DMD are refuted.

Suggested Citation

  • Rosenberg, T. & Jacobs, H.K. & Thompson, R. & Horne, J.M., 1993. "Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy--How does this compare to existing neonatal screening for metabolic disorders?," Social Science & Medicine, Elsevier, vol. 37(4), pages 541-547, August.
    • Handle: RePEc:eee:socmed:v:37:y:1993:i:4:p:541-547
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/0277-9536(93)90289-G
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Angelis, Aris & Tordrup, David & Kanavos, Panos, 2015. "Socio-economic burden of rare diseases: A systematic review of cost of illness evidence," Health Policy, Elsevier, vol. 119(7), pages 964-979.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:socmed:v:37:y:1993:i:4:p:541-547. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/wps/find/journaldescription.cws_home/315/description#description .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.